GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed price. Currency in GBp
1,295.00
+4.50 (+0.35%)
At close: 5:07PM GMT
Stock chart is not supported by your current browser
Previous close1,290.50
Open1,292.50
Bid1,290.00 x 175400
Ask1,310.00 x 417900
Day's range1,287.83 - 1,300.83
52-week range1,270.00 - 1,724.50
Volume15,049,865
Avg. volume10,620,114
Market cap62.88B
Beta1.15
PE ratio (TTM)27.38
EPS (TTM)47.30
Earnings date7 Feb 2018
Forward dividend & yield1.01 (5.14%)
Ex-dividend date2017-08-10
1y target est1,549.93
  • Why I would buy out-of-favour Bunzl plc over GlaxoSmithKline plc
    Fool.co.ukyesterday

    Why I would buy out-of-favour Bunzl plc over GlaxoSmithKline plc

    Harvey Jones reckons Bunzl plc (LON: BNZL) could fly back into favour before fellow struggler GlaxoSmithKline plc (LON: GSK).

  • Glaxo's Nucala Label Expansion Application Gets FDA Approval
    Zacks2 days ago

    Glaxo's Nucala Label Expansion Application Gets FDA Approval

    GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.

  • Glaxo's New Pharma Head Looks to Move Fast, Especially in Cancer
    Bloomberg5 days ago

    Glaxo's New Pharma Head Looks to Move Fast, Especially in Cancer

    GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, signaled it will look to speed development of an experimental cancer treatment as part of its ambition to expand in oncology just two years after selling ...

  • Reuters9 days ago

    Companies prepare for disorderly Brexit as talks stall

    Big companies are stepping up their plans in case Britain crashes out of the European Union without a deal as Prime Minister Theresa May struggles to get talks back on track after a major setback. Britain is aiming to agree with the EU on Dec. 14 to move the Brexit talks on to the second phase. Senior executives in the financial services sector, which accounts for about 12 percent of the economy, told Reuters May's efforts to secure a transition deal had come too late and they had no choice but to start restructuring.

  • Reuters - UK Focus9 days ago

    Companies prepare for disorderly Brexit as talks stall

    LONDON, Dec (Shanghai: 600875.SS - news) 7 (Reuters) - Big companies are stepping up their plans in case Britain crashes out of the European Union without a deal as Prime Minister Theresa May struggles to get talks back on track after a major setback. Britain is aiming to agree with the EU on Dec. 14 to move the Brexit talks on to the second phase. This would focus on trade and a two-year transition deal to smooth the departure after March 2019.

  • Barrons.com9 days ago

    Glaxo Who? Why Gilead's HIV Drug Could Be the 'Greatest of All Time'

    Shares of Gilead Sciences (GILD) are rising Wednesday, helped by a bullish note from Credit Suisse, which argues that its HIV treatment Bictegravir could be a launch that will become "the greatest ...

  • Market Realist9 days ago

    GlaxoSmithKline’s Vaccines Business in 3Q17

    GlaxoSmithKline’s (GSK) Vaccines business reported revenues of ~1.7 billion pounds during 3Q17, reflecting 5.0% growth in revenues compared to 3Q16.

  • GSK, other drugmakers bet on post-Brexit UK science
    Reuters9 days ago

    GSK, other drugmakers bet on post-Brexit UK science

    Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy plans after Brexit. The move is welcome news for Prime Minister Theresa May, who has struggled to win over large sections of industry as Britain prepares to leave the European Union. Thanks to the strength of UK universities and the presence of two major pharmaceuticals companies in GlaxoSmithKline and AstraZeneca, the drugs industry has been a bright spot in the British economy for many years.

  • Reuters - UK Focus9 days ago

    GSK, other drugmakers bet on post-Brexit UK science

    Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy ...

  • Australia takes GSK, Novartis to court over 'misleading' claims
    AFP10 days ago

    Australia takes GSK, Novartis to court over 'misleading' claims

    GSK acquired Novartis' portfolio of Voltaren products in 2016 and has been responsible for marketing and selling them since then

  • Drug Companies From Glaxo to J&J Pledge to Make U.K. Investments
    Bloomberg10 days ago

    Drug Companies From Glaxo to J&J Pledge to Make U.K. Investments

    GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. and AstraZeneca Plc are among more than two dozen global pharmaceutical companies pledging to invest funds in the U.K. as part of a multi-billion-pound ...

  • Australian watchdog takes GlaxoSmithKline, Novartis units to court
    Reuters10 days ago

    Australian watchdog takes GlaxoSmithKline, Novartis units to court

    The ACCC alleged that the companies tried to market their two pain relief products, Osteo Gel and Emulgel, as having different levels of impact in treating osteoarthritis, when in fact they are "identically formulated". "We allege that consumers are likely to have been misled into purchasing Osteo Gel thinking that it is different to Emulgel and more effective for treating osteoarthritis conditions, when this is not the case”, ACCC Chairman Rod Sims said.

  • Reuters - UK Focus10 days ago

    Australia competition watchdog takes GlaxoSmithKline, Novartis units to court

    The Australian Competition and Consumer Commission on Wednesday said it is taking local units of GlaxoSmithKline and Swiss healthcare company Novartis to court over false or misleading representations ...

  • The Wall Street Journal10 days ago

    Glaxo's Karenann Terrell Enlists AI in Understanding HIV Patients

    GlaxoSmithKline is using artificial intelligence to learn why certain HIV patients drop out of treatment. "The only clues that exist are in unstructured types of data," such as doctor's notes, ...

  • Market Realist10 days ago

    GlaxoSmithKline’s Global Pharmaceuticals Business in 3Q17

    The Global Pharmaceuticals business reported revenues of 3.1 billion pounds during 3Q17.

  • Market Realist10 days ago

    GlaxoSmithKline’s HIV Business in 3Q17

    GlaxoSmithKline’s (GSK) HIV business includes products such as Triumeq, Tivicay, Epzicom/Kivexa, and Selzentry.

  • Market Realist11 days ago

    GlaxoSmithKline’s Business Segments in 3Q17

    GlaxoSmithKline’s (GSK) Vaccines segment reported revenues of ~1.7 billion pounds during 3Q17, reflecting 5.0% growth in revenues compared to 3Q16.

  • Market Realist11 days ago

    GlaxoSmithKline’s Quarterly Revenues for 3Q17

    GlaxoSmithKline's (GSK) 3Q17 revenues of ~7.8 billion pounds represented 4.0% growth compared to its 3Q16 revenues of ~7.5 billion pounds.

  • Market Realist11 days ago

    GlaxoSmithKline’s Valuation in November 2017

    In 3Q17, GlaxoSmithKline (GSK) surpassed Wall Street analysts’ estimates for its earnings per share. GSK reported revenues of ~7.8 billion pounds, missing the estimate of 7.9 billion pounds.

  • Is a Dividend Cut Coming From GlaxoSmithKline plc?
    Motley Fool13 days ago

    Is a Dividend Cut Coming From GlaxoSmithKline plc?

    Is the company's rich yield an opportunity for investors, or a warning of trouble ahead?

  • 3 Drug/Biotech Stocks in Focus on World AIDS Day
    Zacks14 days ago

    3 Drug/Biotech Stocks in Focus on World AIDS Day

    On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.

  • Market Realist14 days ago

    Gauging Novartis’s Valuation This November

    Novartis saw revenues of ~$12.4 billion and EPS of $1.29 for 3Q17, which represents a 2% YoY rise, compared with its revenues of ~$12.1 billion in 3Q16.

  • Reuters14 days ago

    FTSE falls in broad risk-off move as Trump worries resurface

    The FTSE fell on Friday at the end of a choppy session that saw Britain's top-share index accelerate losses and join a global risk-off move following reports in the United States that raised new worries over the stability of Donald Trump's administration. The FTSE fell 0.4 percent, having earlier gained as much as 0.4 percent thanks to a pull back in the pound that helped it recover from the losses seen in morning trade. ABC News reported that former U.S. national security adviser Michael Flynn was prepared to testify that Trump directed him to make contact with Russians when he was a presidential candidate.

  • Reuters - UK Focus14 days ago

    FTSE falls in broad risk-off move as Trump worries resurface

    The FTSE fell on Friday at the end of a choppy session that saw Britain's top-share index accelerate losses and join a global risk-off move following reports in the United States that raised new worries ...

  • Glaxo Begins Phase III Study on Injection to Prevent HIV
    Zacks14 days ago

    Glaxo Begins Phase III Study on Injection to Prevent HIV

    Glaxo (GSK) announces start of a large late-stage African study on an experimental long-acting injection for the prevention of HIV.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes